Full Press Release Details
REYKJAVIK,ICELAND (April 24, 2026)— Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. market close.
The Company will also host a webcast with a live Q&A on Thursday, May 7, 2026, at 08:00 EST (12:00 GMT, 13:00 BST, 14:00 CEST).
• To listen to the webcast, please register here:Q1 2026 webcast registration
• To participate in the Q&A, please register here:Q1 2026 conference call registration
Slides and other material will be made available oninvestors.alvotech.com/eventsbefore the call.
For further information, contact:
MediaBenedikt StefanssonSarah MacLeodalvotech.media@alvotech.com
InvestorsDr. Balaji V Prasad (US)Patrik Ling (SE)Benedikt Stefansson (IS)alvotech.ir@alvotech.com
About AlvotechAlvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visithttps://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit ourinvestor portal, and ourwebsiteor follow us on social media onLinkedIn,Facebook,InstagramandYouTube.